CN101027301B - 稠环氮杂十氢化萘糖皮质激素受体调节剂 - Google Patents
稠环氮杂十氢化萘糖皮质激素受体调节剂 Download PDFInfo
- Publication number
- CN101027301B CN101027301B CN2005800114815A CN200580011481A CN101027301B CN 101027301 B CN101027301 B CN 101027301B CN 2005800114815 A CN2005800114815 A CN 2005800114815A CN 200580011481 A CN200580011481 A CN 200580011481A CN 101027301 B CN101027301 B CN 101027301B
- Authority
- CN
- China
- Prior art keywords
- substituted
- unsubstituted
- compound
- tert
- fluorophenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *I(C1(C*(CCC23)N)C2[C@@]3C2=CC=CC=CC2C1)=* Chemical compound *I(C1(C*(CCC23)N)C2[C@@]3C2=CC=CC=CC2C1)=* 0.000 description 14
- DEMROIUOHAMDAU-INIZCTEOSA-N CC(C)(C)OC(N(CC1)C[C@](CC2)(C(OC)=O)C1=CC2=O)=O Chemical compound CC(C)(C)OC(N(CC1)C[C@](CC2)(C(OC)=O)C1=CC2=O)=O DEMROIUOHAMDAU-INIZCTEOSA-N 0.000 description 1
- OMUUYSVGVAHHRG-GQHPKTMLSA-N CC(C)(C)c(cc1)ccc1S(N(CC1)C[C@@](Cc2ccccc2)(C/C2=C/O)C1=CC2=O)(=O)=O Chemical compound CC(C)(C)c(cc1)ccc1S(N(CC1)C[C@@](Cc2ccccc2)(C/C2=C/O)C1=CC2=O)(=O)=O OMUUYSVGVAHHRG-GQHPKTMLSA-N 0.000 description 1
- OVINOJFNXOBWGQ-YTTGMZPUSA-N CC(C)(C)c(cc1)ccc1SN(CC1)C[C@@](CN2CCCCC2)(C2)C1=Cc1c2cn[n]1-c(cc1)ccc1F Chemical compound CC(C)(C)c(cc1)ccc1SN(CC1)C[C@@](CN2CCCCC2)(C2)C1=Cc1c2cn[n]1-c(cc1)ccc1F OVINOJFNXOBWGQ-YTTGMZPUSA-N 0.000 description 1
- KPRWXFRVAQXBJU-YTTGMZPUSA-N CC(C)(C)c(cc1)ccc1[SH-]N(CC1)C[C@@](CN(C)CCN(C)C)(C2)C1=Cc1c2cn[n]1-c(cc1)ccc1F Chemical compound CC(C)(C)c(cc1)ccc1[SH-]N(CC1)C[C@@](CN(C)CCN(C)C)(C2)C1=Cc1c2cn[n]1-c(cc1)ccc1F KPRWXFRVAQXBJU-YTTGMZPUSA-N 0.000 description 1
- MJWIXFUKOMHBKQ-UHFFFAOYSA-N CC(C)(C)c(cc12)ccc1S2N(CC1)CC(C2)(C(O)=O)C1=Cc1c2cn[n]1-c(cc1)ccc1F Chemical compound CC(C)(C)c(cc12)ccc1S2N(CC1)CC(C2)(C(O)=O)C1=Cc1c2cn[n]1-c(cc1)ccc1F MJWIXFUKOMHBKQ-UHFFFAOYSA-N 0.000 description 1
- BDLVQIWUDHVZLI-QPJQQBGISA-N CCC(C/C=C(\C)/F)[n]1ncc(C2)c1C=C(CC1)C2(CNCCO)CN1[IH]S(C1=CCC(C(C)(C)C)C#C1)=O Chemical compound CCC(C/C=C(\C)/F)[n]1ncc(C2)c1C=C(CC1)C2(CNCCO)CN1[IH]S(C1=CCC(C(C)(C)C)C#C1)=O BDLVQIWUDHVZLI-QPJQQBGISA-N 0.000 description 1
- RCXABSKLIPMFLV-UHFFFAOYSA-O Cc(c(C1)c2C=C(CC3)C1(Cc(cc1)ccc1F)CN3[SH+]c1ccccc1)n[n]2-c(cc1)ccc1F Chemical compound Cc(c(C1)c2C=C(CC3)C1(Cc(cc1)ccc1F)CN3[SH+]c1ccccc1)n[n]2-c(cc1)ccc1F RCXABSKLIPMFLV-UHFFFAOYSA-O 0.000 description 1
- CYJQALDXBCTBAN-AYTRYJACSA-N Cc(cc1)ccc1S(N(CC1)C[C@@](CN(C)C)(C2)C1=Cc1c2cn[n]1-c(cc1)ccc1F)=O Chemical compound Cc(cc1)ccc1S(N(CC1)C[C@@](CN(C)C)(C2)C1=Cc1c2cn[n]1-c(cc1)ccc1F)=O CYJQALDXBCTBAN-AYTRYJACSA-N 0.000 description 1
- SKESTLBPFVXIPV-UHFFFAOYSA-N Fc1ccc(CC(C2)(CN(Cc3ccncc3)CC3)C3=Cc3c2cn[n]3-c(cc2)ccc2F)cc1 Chemical compound Fc1ccc(CC(C2)(CN(Cc3ccncc3)CC3)C3=Cc3c2cn[n]3-c(cc2)ccc2F)cc1 SKESTLBPFVXIPV-UHFFFAOYSA-N 0.000 description 1
- CAQZKKFKRSDNRB-HOCLYGCPSA-N O=C(CC1)C[C@H]2[C@@]1(Cc1ccccc1)CNCC2 Chemical compound O=C(CC1)C[C@H]2[C@@]1(Cc1ccccc1)CNCC2 CAQZKKFKRSDNRB-HOCLYGCPSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Virology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55183604P | 2004-03-09 | 2004-03-09 | |
| US60/551,836 | 2004-03-09 | ||
| PCT/US2005/008049 WO2005087769A1 (en) | 2004-03-09 | 2005-03-09 | Fused ring azadecalin glucocorticoid receptor modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101027301A CN101027301A (zh) | 2007-08-29 |
| CN101027301B true CN101027301B (zh) | 2011-06-29 |
Family
ID=34961932
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2005800114815A Expired - Fee Related CN101027301B (zh) | 2004-03-09 | 2005-03-09 | 稠环氮杂十氢化萘糖皮质激素受体调节剂 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US7928237B2 (https=) |
| EP (1) | EP1735308B1 (https=) |
| JP (1) | JP4931794B2 (https=) |
| KR (1) | KR101185281B1 (https=) |
| CN (1) | CN101027301B (https=) |
| AT (1) | ATE407934T1 (https=) |
| AU (1) | AU2005222421B2 (https=) |
| CA (1) | CA2558899C (https=) |
| CY (1) | CY1108621T1 (https=) |
| DE (1) | DE602005009687D1 (https=) |
| DK (1) | DK1735308T3 (https=) |
| ES (1) | ES2313317T3 (https=) |
| IL (1) | IL177982A (https=) |
| NZ (1) | NZ550362A (https=) |
| PT (1) | PT1735308E (https=) |
| WO (1) | WO2005087769A1 (https=) |
| ZA (1) | ZA200608306B (https=) |
Families Citing this family (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005222421B2 (en) * | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| TWI410422B (zh) * | 2007-01-15 | 2013-10-01 | Mitsubishi Tanabe Pharma Corp | 縮合四氫喹啉衍生物及其醫藥用途 |
| EP2532350A1 (en) | 2007-10-17 | 2012-12-12 | Laboratoire HRA Pharma | Pharmaceutical combination of a glucocorticoid receptor antagonist and a cortisol synthesis inhibitor for treating cushing's syndrome |
| US9216221B2 (en) | 2008-11-07 | 2015-12-22 | University Of Sheffield | Medicament and method of diagnosis for treating subclinical Cushing's syndrome |
| ES2531040T3 (es) * | 2009-05-12 | 2015-03-10 | Corcept Therapeutics Inc | Formas sólidas y procedimiento de preparación |
| EP2493303A4 (en) * | 2009-10-30 | 2013-06-26 | Merck Sharp & Dohme | 2- [1-PHENYL-5-HYDROXY-4A-SUBSTITUTED HEXAHYDROCYCLOPENTA [F] INDAZOL-5-YL] ETHYLPHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS |
| WO2011087946A1 (en) * | 2010-01-15 | 2011-07-21 | Rigel Pharmaceuticals, Inc. | Screening assay employing dex and gdf8 |
| KR20130106378A (ko) * | 2010-08-27 | 2013-09-27 | 코어셉트 쎄라퓨틱스, 잉크. | 피리딜-아민 융합된 아자데칼린 조절제 |
| US8829024B2 (en) | 2011-01-07 | 2014-09-09 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| US9006568B2 (en) * | 2012-02-15 | 2015-04-14 | Phillips 66 Company | Synthesis of photovoltaic conjugated polymers |
| US20130225633A1 (en) * | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| US12226412B2 (en) | 2012-05-25 | 2025-02-18 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PT4119561T (pt) * | 2012-05-25 | 2024-09-30 | Corcept Therapeutics Inc | Moduladores de recetores de glucocorticoides de azadecalina fundida com heteroaril-cetona |
| US9691986B2 (en) | 2012-12-03 | 2017-06-27 | Solarmer Energy, Inc. | Furan and selenophene derivatized benzo [1,2-b:4,5-b′] dithiophene-thienothiophene based conjugated polymers for high-efficiency organic solar cells |
| FI3848027T3 (fi) * | 2013-11-25 | 2023-05-04 | Corcept Therapeutics Inc | Oktahydrofuusioituja atsadekaliiniglukokortikoidireseptorin modulaattoreita |
| WO2015077537A1 (en) * | 2013-11-25 | 2015-05-28 | Corcept Therapeutics, Inc. | Heteroaryl-ether fused azadecalin glucocorticoid receptor modulators |
| CN107530435A (zh) * | 2015-03-02 | 2018-01-02 | 科赛普特治疗学股份有限公司 | 使用糖皮质激素受体拮抗剂和生长抑素治疗acth分泌型肿瘤 |
| WO2016160969A1 (en) | 2015-03-30 | 2016-10-06 | Corcept Therapeutics, Inc. | Use of glucocorticoid receptor antagonists in combination with glucocorticoids to treat adrenal insufficiency |
| ES2865334T3 (es) | 2015-08-13 | 2021-10-15 | Corcept Therapeutics Inc | Método de diagnóstico diferencial de síndrome de Cushing dependiente de ACTH |
| US10312448B2 (en) | 2015-10-01 | 2019-06-04 | Phillips 66 Company | Process of manufacturing an electron transport material |
| US9905769B2 (en) | 2015-10-01 | 2018-02-27 | Phillips 66 Company | Process of manufacturing an electron transport material |
| WO2017058406A1 (en) | 2015-10-01 | 2017-04-06 | Phillips 66 Company | Formation of films for organic photovoltaics |
| US9911919B2 (en) | 2015-10-01 | 2018-03-06 | Phillips 66 Company | Process of manufacturing an electron transport material |
| US10418555B2 (en) | 2015-10-01 | 2019-09-17 | Phillips 66 Company | Formation of films for organic photovoltaics |
| CA3011728A1 (en) | 2016-01-19 | 2017-07-27 | Corcept Therapeutics, Inc. | Differential diagnosis of ectopic cushing's syndrome |
| IL297201A (en) | 2016-03-01 | 2022-12-01 | Corcept Therapeutics Inc | Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
| JP7564620B2 (ja) | 2017-03-09 | 2024-10-09 | コーセプト セラピューティクス， インコーポレイテッド | カテコールアミン分泌腫瘍の処置における糖質コルチイド受容体モジレータの使用 |
| CA3055076C (en) | 2017-03-31 | 2022-02-22 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat cervical cancer |
| AU2018289307B2 (en) | 2017-06-20 | 2024-02-01 | Corcept Therapeutics, Inc. | Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators |
| IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
| WO2020132046A1 (en) | 2018-12-19 | 2020-06-25 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| US11234971B2 (en) | 2018-12-19 | 2022-02-01 | Corcept Therapeutics Incorporated | Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent |
| FI3897589T3 (fi) | 2018-12-19 | 2026-01-13 | Corcept Therapeutics Inc | Farmaseuttisia formulaatioita, jotka sisältävät relakorilanttia, heteroaryyliketonifusoitua atsekaliiniyhdistettä |
| JP7789561B2 (ja) | 2019-02-22 | 2025-12-22 | コーセプト セラピューティクス， インコーポレイテッド | レラコリラント、ヘテロアリール－ケトン縮合アザデカリングルココルチコイド受容体調節物質の治療用途 |
| AU2020239920A1 (en) | 2019-03-18 | 2021-11-04 | Arnold L. Newman | Method of improving insulin sensitivity |
| WO2021076565A1 (en) | 2019-10-16 | 2021-04-22 | Corcept Therapeutics Incorporated | Method of normalizing the neutrophil to lymphocyte ratio in cancer patients with a selective glucocorticoid receptor antagonist |
| PH12022551430A1 (en) | 2019-12-11 | 2023-11-20 | Corcept Therapeutics Inc | Methods of treating antipsychotic-induced weight gain with miricorilant |
| US20230358768A1 (en) | 2019-12-21 | 2023-11-09 | Corcept Therapeutics Incorporated | Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome |
| BR112022015011A2 (pt) | 2020-01-29 | 2022-09-20 | Corcept Therapeutics Inc | Método para tratar um sujeito que sofre de tumor de carcinoma adrenocortical e tendo excesso de cortisol, e, composição farmacêutica para tratar carcinoma adrenocortical |
| CA3166901A1 (en) * | 2020-02-10 | 2021-08-19 | Corcept Therapeutics Incorporated | Methods of stimulating an anti-tumor response using a selective glucocorticoid receptor modulator |
| US11285145B2 (en) | 2020-05-27 | 2022-03-29 | Corcept Therapeutics Incorporated | Concomitant administration of glucocorticoid receptor modulator relacorilant and paclitaxel, a dual substrate of CYP2C8 and CYP3A4 |
| AU2021296163B2 (en) | 2020-06-22 | 2024-07-04 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| WO2022081725A1 (en) * | 2020-10-16 | 2022-04-21 | The Scripps Research Institute | Therapeutic uses of glucocorticoids with anabolic effects in skeletal muscle |
| WO2022134033A1 (en) | 2020-12-25 | 2022-06-30 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| WO2022166810A1 (zh) * | 2021-02-03 | 2022-08-11 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| CN114907340A (zh) * | 2021-02-09 | 2022-08-16 | 江苏恒瑞医药股份有限公司 | 稠合的氮杂三环类衍生物、其制备方法及其在医药上的应用 |
| IL313663A (en) | 2021-12-21 | 2024-08-01 | Corcept Therapeutics Inc | Piperazine indazole glucocorticoid receptor antagonists |
| KR20240125035A (ko) | 2021-12-21 | 2024-08-19 | 코어셉트 쎄라퓨틱스 인코포레이티드 | 이환 인다졸 글루코코르티코이드 수용체 길항제 |
| AU2023301396A1 (en) * | 2022-06-28 | 2024-12-12 | Corcept Therapeutics Incorporated | Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| CN117510490A (zh) * | 2022-08-03 | 2024-02-06 | 江苏恒瑞医药股份有限公司 | 一种稠合氮杂萘烷类衍生物的晶型及其制备方法 |
| IL319657A (en) | 2022-10-06 | 2025-05-01 | Corcept Therapeutics Inc | Glucocorticoid receptor modulator formulations |
| WO2024092195A1 (en) | 2022-10-28 | 2024-05-02 | Corcept Therapeutics Incorporated | Treatments for amyotrophic lateral sclerosis using dazucorilant |
| CN120787227A (zh) * | 2023-02-24 | 2025-10-14 | 科赛普特治疗公司 | 制备杂芳基-酮稠合的氮杂萘烷糖皮质激素受体调节剂的中间体的方法 |
| WO2025152964A1 (en) * | 2024-01-15 | 2025-07-24 | Insilico Medicine Ip Limited | Novel compounds as glucocorticoid receptor modulators and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8828669D0 (en) * | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| EP1512683B1 (en) * | 1998-03-10 | 2011-08-31 | Research Triangle Institute | Novel opiate compounds, methods of making and methods of use |
| GB9911053D0 (en) * | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| CA2473886C (en) * | 2002-01-22 | 2012-08-21 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| AU2005222421B2 (en) * | 2004-03-09 | 2010-09-23 | Corcept Therapeutics, Inc. | Fused ring azadecalin glucocorticoid receptor modulators |
| ES2531040T3 (es) * | 2009-05-12 | 2015-03-10 | Corcept Therapeutics Inc | Formas sólidas y procedimiento de preparación |
-
2005
- 2005-03-09 AU AU2005222421A patent/AU2005222421B2/en not_active Ceased
- 2005-03-09 AT AT05725295T patent/ATE407934T1/de active
- 2005-03-09 KR KR1020067020988A patent/KR101185281B1/ko not_active Expired - Fee Related
- 2005-03-09 CA CA2558899A patent/CA2558899C/en not_active Expired - Lifetime
- 2005-03-09 DK DK05725295T patent/DK1735308T3/da active
- 2005-03-09 JP JP2007503030A patent/JP4931794B2/ja not_active Expired - Fee Related
- 2005-03-09 PT PT05725295T patent/PT1735308E/pt unknown
- 2005-03-09 DE DE602005009687T patent/DE602005009687D1/de not_active Expired - Lifetime
- 2005-03-09 ES ES05725295T patent/ES2313317T3/es not_active Expired - Lifetime
- 2005-03-09 WO PCT/US2005/008049 patent/WO2005087769A1/en not_active Ceased
- 2005-03-09 US US10/591,884 patent/US7928237B2/en active Active
- 2005-03-09 NZ NZ550362A patent/NZ550362A/en not_active IP Right Cessation
- 2005-03-09 EP EP05725295A patent/EP1735308B1/en not_active Expired - Lifetime
- 2005-03-09 CN CN2005800114815A patent/CN101027301B/zh not_active Expired - Fee Related
-
2006
- 2006-09-10 IL IL177982A patent/IL177982A/en active IP Right Grant
- 2006-10-05 ZA ZA200608306A patent/ZA200608306B/xx unknown
-
2008
- 2008-12-05 CY CY20081101413T patent/CY1108621T1/el unknown
-
2011
- 2011-03-11 US US13/046,529 patent/US20110166110A1/en not_active Abandoned
-
2012
- 2012-05-21 US US13/476,776 patent/US8557839B2/en not_active Expired - Fee Related
-
2013
- 2013-09-12 US US14/025,459 patent/US20140179671A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ550362A (en) | 2010-06-25 |
| KR20070029684A (ko) | 2007-03-14 |
| US20140179671A1 (en) | 2014-06-26 |
| ZA200608306B (en) | 2009-02-25 |
| US20110166110A1 (en) | 2011-07-07 |
| US7928237B2 (en) | 2011-04-19 |
| EP1735308A1 (en) | 2006-12-27 |
| CA2558899A1 (en) | 2005-09-22 |
| US20120225856A1 (en) | 2012-09-06 |
| HK1104813A1 (en) | 2008-01-25 |
| IL177982A (en) | 2012-09-24 |
| EP1735308B1 (en) | 2008-09-10 |
| ES2313317T3 (es) | 2009-03-01 |
| CN101027301A (zh) | 2007-08-29 |
| AU2005222421A1 (en) | 2005-09-22 |
| CY1108621T1 (el) | 2014-04-09 |
| KR101185281B1 (ko) | 2012-09-21 |
| DE602005009687D1 (de) | 2008-10-23 |
| PT1735308E (pt) | 2008-12-02 |
| JP2007528417A (ja) | 2007-10-11 |
| US8557839B2 (en) | 2013-10-15 |
| AU2005222421B2 (en) | 2010-09-23 |
| WO2005087769A1 (en) | 2005-09-22 |
| CA2558899C (en) | 2013-02-05 |
| ATE407934T1 (de) | 2008-09-15 |
| IL177982A0 (en) | 2006-12-31 |
| JP4931794B2 (ja) | 2012-05-16 |
| US20070281928A1 (en) | 2007-12-06 |
| DK1735308T3 (da) | 2009-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101027301B (zh) | 稠环氮杂十氢化萘糖皮质激素受体调节剂 | |
| US12139486B2 (en) | Octahydro fused azadecalin glucocorticoid receptor modulators | |
| US8324203B2 (en) | Azadecalin glucocorticoid receptor modulators | |
| US8598154B2 (en) | Pyridyl-amine fused azadecalin modulators | |
| JP4958774B2 (ja) | 改変されたピリミジン糖質コルチコイドレセプター調節因子 | |
| HK1104813B (en) | Fused ring azadecalin glucocorticoid receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110629 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |